PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson’s disease

Objective: To differentiate the patterns of dopamine transporter loss between idiopathic PD and progressive supranuclear palsy (PSP). Methods: We used the radiotracer [11C]-WIN 35,428 and PET. Regional striatal dopamine transporter binding was measured in the caudate, anterior putamen, and posterior putamen of six patients with L-dopa–responsive stage 2 PD, six patients with PSP, and six age-comparable healthy controls. Results: In patients with idiopathic PD, the most marked abnormality was observed in the posterior putamen (77% reduction), whereas transporter density in the anterior putamen (60% reduction) and the caudate (44% reduction) was less affected. Unlike the patients with PD, the PSP group showed a relatively uniform degree of involvement in the caudate (40% reduction), anterior putamen (47% reduction), and posterior putamen (51% reduction). When posterior putamen/caudate ratios were calculated, these values were significantly lower in patients with PD than they were in patients with PSP (p = 0.0008) and the control group (p < 0.0001). Conclusions: Patients with PD have a more pronounced loss of dopamine transporters in the posterior putamen due to a subdivisional involvement of nigrostriatal dopaminergic projections in idiopathic PD. This technique is useful in the determination of neurochemical changes underlying PD and PSP, thus differentiating between them.

[1]  G. E. Alexander,et al.  Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. , 1990, Progress in brain research.

[2]  R. Koeppe,et al.  In Vivo Imaging of Vesicular Monoamine Transporters in Human Brain Using [11C]Tetrabenazine and Positron Emission Tomography , 1993, Journal of neurochemistry.

[3]  M Laruelle,et al.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Palacios,et al.  Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. , 1994, Journal of neural transmission. Supplementum.

[5]  M. Ehlers,et al.  Effect of dopaminergic drugs on the in vivo binding of [3H]WIN 35,428 to central dopamine transporters , 1996, Synapse.

[6]  B. Pate,et al.  Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow , 1991, Annals of neurology.

[7]  J. Rinne,et al.  Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra , 1989, Annals of neurology.

[8]  K. Leenders Parkinson's disease and PET tracer studies. , 1988, Journal of neural transmission. Supplementum.

[9]  S H Snyder,et al.  Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's disease , 1993, Annals of neurology.

[10]  Alan C. Evans,et al.  Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[18F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to Normal Subjects , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  D J Brooks,et al.  Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[12]  R. Sperling,et al.  Cerebral perfusion in progressive supranuclear palsy. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  A. Rajput,et al.  Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[14]  Scott T. Grafton,et al.  Kinetics and Modeling of l-6-[18F]Fluoro-DOPA in Human Positron Emission Tomographic Studies , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[16]  B. Snow,et al.  Criteria for diagnosing Parkinson's disease , 1992, Annals of neurology.

[17]  D B Calne,et al.  Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. , 1991, Archives of neurology.

[18]  N. Volkow,et al.  Dopamine transporters decrease with age. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  W. Gibb Neuropathology of Parkinson's disease and related syndromes. , 1992, Neurologic clinics.

[20]  A J Lees,et al.  Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. , 1988, Brain : a journal of neurology.

[21]  Y. Agid,et al.  Loss of Striatal [76Br]Bromospiperone Binding Sites Demonstrated by Positron Tomography in Progressive Supranuclear Palsy , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  T Jones,et al.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[23]  Max B. Streifler,et al.  Parkinson's disease : anatomy, pathology and therapy , 1990 .

[24]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[25]  A. Graybiel,et al.  The nigrostriatal system in Parkinson's disease. , 1990, Advances in neurology.

[26]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[27]  S. Gilman,et al.  Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging , 1996, Annals of neurology.

[28]  E. Tolosa,et al.  Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy ( , 2022 .

[29]  J C Mazziotta,et al.  6‐[18F]Fluoro‐L‐DOPA probes dopamine turnover rates in central dopaminergic structures , 1990, Journal of neuroscience research.

[30]  Alan A. Wilson,et al.  Synthesis of a radiotracer for studying dopamine uptake sites in vivo using PET: 2β‐carbomethoxy‐3β‐(4‐fluorophenyl)‐[N‐11C‐methyl]tropane ([11C]CFT or [11C]WIN‐35,428) , 1993 .

[31]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[32]  S. Kish,et al.  Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.

[33]  J D Speelman,et al.  Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. , 1993, Archives of neurology.

[34]  A. Levey,et al.  Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease , 1996, Neurology.

[35]  C. Cotman,et al.  Synapse replacement in the nervous system of adult vertebrates. , 1981, Physiological reviews.

[36]  S. Goto,et al.  Subdivisional involvement of nigrostriatal loop in idiopathic parkinson's disease and striatonigral degeneration , 1989, Annals of neurology.